Investigational Therapies
Showing 1 - 25 of >10,000
l Gene Editing Therapy for Cardiovascular Disease
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +2 more
-
Auckland, New Zealand
- +2 more
Oct 31, 2023
Neurodermatitis Trial in Worldwide (Dupilumab SAR231893, Placebo, Moisturizers)
Completed
- Neurodermatitis
- Dupilumab SAR231893
- +4 more
-
Gilbert, Arizona
- +62 more
Nov 11, 2022
Tumors Trial in Gainesville, Waterloo, Springfield (Screening Platform)
Terminated
- Neoplasms
- Screening Platform
-
Gainesville, Florida
- +2 more
Dec 1, 2022
Squamous Cell Carcinoma of Head and Neck Trial in Worldwide (Pembrolizumab (Keytruda®), SAR444245 (Thor-707), Cetuximab
Active, not recruiting
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab (Keytruda®)
- +2 more
-
Duarte, California
- +39 more
Oct 31, 2022
Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma Trial in Worldwide (THOR-707, Pembrolizumab,
Active, not recruiting
- Oesophageal Squamous Cell Carcinoma
- +4 more
- THOR-707
- +2 more
-
Duarte, California
- +39 more
Oct 31, 2022
Asthma Trial in China, India (Dupilumab SAR231893, Placebo, Asthma Controller Therapies (include prednisone/prednisolone))
Completed
- Asthma
- Dupilumab SAR231893
- +3 more
-
Baotou, China
- +66 more
Dec 23, 2022
Targeted Therapies in BRAF Positive Metastatic Melanoma in US
Active, not recruiting
- Melanoma
- Encorafenib
- +5 more
-
New York, New YorkPfizer Investigational Site
Feb 18, 2022
Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (biological, drug, other)
Recruiting
- Metastatic Castration-Resistant Prostate Cancer
- Pembrolizumab 200 mg
- +11 more
-
Los Angeles, California
- +30 more
Aug 12, 2022
Chronic Rhinosinusitis With Nasal Polyps Trial in Japan (Dupilumab SAR231893)
Active, not recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Dupilumab SAR231893
-
Japan, JapanInvestigational site JAPAN
Jul 28, 2022
Neurodermatitis Trial in Worldwide (Dupilumab SAR231893, Placebo, Moisturizers)
Completed
- Neurodermatitis
- Dupilumab SAR231893
- +4 more
-
Fort Smith, Arkansas
- +56 more
Dec 2, 2021
Atopic Dermatitis Trial in Japan (Placebo, Dupilumab SAR231893)
Active, not recruiting
- Atopic Dermatitis
- Placebo
- Dupilumab SAR231893
-
Nagoya-shi, Aichi, Japan
- +19 more
Jul 27, 2022
Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)
Terminated
- Chronic Myeloid Leukemia
- Omacetaxine mepesuccinate
-
Jacksonville, Florida
- +9 more
Nov 6, 2021
Advanced Malignant Tumors Lymphomas Trial in United States (IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody
Recruiting
- Advanced Malignant Tumors Lymphomas
- IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
-
Los Angeles, California
- +3 more
Aug 23, 2022
Glycogen Storage Disease Type II;Pompe's Disease Trial in Worldwide (Avalglucosidase alfa (GZ402666), Alglucosidase alfa
Active, not recruiting
- Glycogen Storage Disease Type II;Pompe's Disease
- Avalglucosidase alfa (GZ402666)
- Alglucosidase alfa (GZ419829)
-
Phoenix, Arizona
- +68 more
May 3, 2022
Hypercholesterolemia Trial in Worldwide (ALIROCUMAB SAR236553 (REGN727), (for injection training only), ezetimibe)
Completed
- Hypercholesterolemia
- ALIROCUMAB SAR236553 (REGN727)
- +5 more
-
Graz, Austria
- +152 more
Mar 21, 2022
Tumors Trial in Worldwide (GSK adoptive cell therapy)
Recruiting
- Neoplasms
- GSK adoptive cell therapy
-
Duarte, California
- +37 more
Feb 1, 2022
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis Trial in United States (AK002, Placebo)
Active, not recruiting
- Eosinophilic Duodenitis
- Eosinophilic Gastroenteritis
- AK002
- Placebo
-
Birmingham, Alabama
- +38 more
Dec 16, 2021
Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,
Recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- Pembrolizumab
- +5 more
-
Milan, Lombardia, Italy
- +13 more
Jan 3, 2023
Breast Cancer Metastatic Trial in Worldwide (Amcenestrant, Fulvestrant, Anastrozole)
Active, not recruiting
- Breast Cancer Metastatic
- Amcenestrant
- +5 more
-
Birmingham, Alabama
- +121 more
Apr 28, 2022
Covid19, Cytokine Release Syndrome, Critical Illness Trial in Rawalpindi (procedure, biological, drug)
Completed
- Covid19
- +3 more
- Therapeutic Plasma exchange
- +4 more
-
Rawalpindi, Punjab, PakistanPak Emirates Military Hospital
Jul 28, 2020
Pancreatic Cancer Trial in Gainesville (Chemotherapy, Chemotherapy + ChemoRadiotherapy)
Completed
- Pancreatic Cancer
- Chemotherapy
- Chemotherapy + ChemoRadiotherapy
-
Gainesville, FloridaUniversity of Florida Shands Cancer Center
Jan 21, 2020